- Questcor Pharmaceuticals (QCOR -1.8%) is weaker on the session on the heels of (another) negative Citron Research piece.
- Citron says it plans to release "a series of articles" about the company "over the coming months," but this particular piece relates to the issue of the FTC, Acthar, and Synacthen (for background on this, see here).
- Ultimately, Citron says the "smoking gun" in terms of whether QCOR's Synacthen acquisition is anti-competitive is a study allegedly cited by the company last year when it was "ramping up its nephrology sales initiative."
- "The referenced study for Nephritic Syndrome specifically stated that Synacthen — not Acthar — was the drug used in the trial. So at that time, QCOR was justifying Acthar's use for Nephrotic conditions specifically because it was a correlate to Synacthen," Citron claims.
- Full report here.
Questcor slips as Citron goes back on the offensive
Dec 4 2013, 14:36 ET